Beyond Type 1 Advocacy
We Believe
Everyone impacted by diabetes—type 1, type 2 and beyond—has a right to the best care possible for their unique situation. This means having access to the technology, medications, support, and clinical care teams that help each individual manage their chronic condition. We work to increase access and remove barriers, giving our community the tools needed to succeed.
High quality, modern insulin must be available to people with diabetes regardless of employment or insurance status, across all demographics, without barriers and at an affordable and predictable price point.
Our advocacy work focuses on equity: making sure people with diabetes have access to care by tackling issues like systemic racism, financial privilege and discrimination in all its forms.
Federal Actions
If Congress doesn’t hear about what matters to our community, they won’t take action. Sending messages to your elected representatives is one of many ways to raise your voice on important issues impacting people with diabetes. The latest actions available are listed below, but keep checking back, as new bills are introduced often.
What you can do right now: fill out your name and street address and click next. Our grassroots platform will find your elected representatives and walk you through sending a message to let them know your thoughts!
State Actions
States have power over our health through budgets and bills, so it’s just as important to let our state representatives know how their decisions can impact our daily diabetes management.
State insulin price capping bills have been one way to provide financial relief to some members of our community. However, these bills only assist those who have select state-regulated commercial insurance. To learn more about the limitations of insulin capping bills, click here.
We are actively monitoring these state insulin price capping bills (listed below), as we believe that even helping a few community members with out-of-pocket costs is one step closer to ensuring all people with diabetes in the United Sates have affordable access to insulin. If you’re interested in learning more about a particular bill and where it stands in the state’s legislature process, click on the name of the bill.
Letters + Coalitions
Beyond Type 1 has weighed in on the latest policy measures through sign-on letters and public comments:
- Support Letter to CA Budget Committee for CGM Access/AB 97 (5/22)
- Support Letter to AMA re: Biomarker Testing for DKD (4/22)
- Support Letter to Nebraska Legislative Assembly for Medicaid CGM Coverage (2/22)
- Request Letter to Gov. Newsom (CA) to sign SB 97 into law (10/21)
- Comment Letter to Senate Finance on Drug Pricing Proposals (10/21)
- Support Letter to CMS for Telemedicine Expansion and MDPP Issues (9/21)
- Request Letter to CMS to Reinstate Insulin Savings Filter to Medicare Plan Finder (9/21)
- Comment Letter to CDC on COVID-19 Booster Vaccines (8/21)
- Support Letter to HHS/CMS re: Biosimilar Zero Copay Policy (8/21)
- Support Letter for California SB 97 (7/21)
- Support Letter for Medicare Part D Biosimilar Tiering (7/21)
- Support Letter to HHS Sec. Becerra re: Patient Drug Affordability (7/21)
- Comment Letter to RFI on Prescription Drug Cost Reporting (7/21)
- Support Letter for Teplizumab for FDA Advisory Committee Meeting (5/21)
- Comment Letter on Proposed Bill ME LD 673 Insulin Safety Net Program (5/21)
- Comment Letter to MACPAC to Reject Medicaid Rebate Recommendation (4/21)
- Comment Letter on Proposed Bill ME LD 673 Insulin Safety Net Program (4/21)
- Comment Letter to Cigna on Non-Medical Switching of Prescription Drugs (4/21)
- Open Letter to Reject Harmful Legislation Referencing QALY Metrics (4/21)
- Comment Letter to Senate HELP Committee on SDOH Funding (4/21)
- Comment Letter on CDC COVID-19 Vaccine Diabetes Prioritization (3/21)
- CGM Medi-CAL Coverage Letter (2/21)
- Comment Letter on CMS Proposed Rule Changes for CGM Coverage (1/21)
- PIPC Stakeholder Comment on Opposing Importing QALYs (1/21)
- SHCC Biden Transition Letter (12/20)
- Telehealth Access during COVID-19 Emergency to AHIP (11/20)
Beyond Type 1 is an active member of the following advocacy coalitions:
- Alliance to Modernize Prescribing Information (AMPI)
- Diabetes Technology Access Coalition
- DLC Healthcare Reform
- Diabetes Policy Collaborative (DPC)
- International Alliance for Diabetes Action (IADA)
- Partnership to Improve Patient Care (PIPC)
- Smarter Healthcare Coalition
- Technology Access Project
- Time In Range Coalition (TIRC)
Resources
GetInsulin.org
A program of Beyond Type 1, connecting people with diabetes who take insulin to assistance programs and low-cost solutions that match their unique situation. MORE
Drug Rebates, Insulin and Affording Life with Diabetes in the United States
The issues surrounding drug rebates in the U.S. highlight the need for reform, especially when it comes to insulin and living with diabetes.MORE
The United States’ Insulin Crisis
Whether you need insulin right now or want to lend your voice to the fight for affordable, consistent access to insulin in the US, start here.MORE
How Insulin Pricing Works in the U.S.
The American healthcare system has created a complex web of players who exchange money for pharmaceutical products in ways that are not entirely clear.MORE
Coverage 2 Control
Join the Coverage 2 Control campaign from JDRF, and tell insurance companies to provide affordability, choice and coverage to help people with type 1 diabetes (T1D) better control the disease.MORENews
The Affordable Insulin Now Act: A Step Toward Federal Legislation
The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE
The Potential Impact of Build Back Better on American Healthcare
Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MORE
Inside the Senate Report on Rising Insulin Prices
A January 2021 Senate Finance Committee report dug into the rapidly increasing cost of insulin. Here, we summarize and explain their findings.MORE
Get the Facts on Insulin Pricing + The Presidential Transition
A flurry of misinformation is stoking fears that the Biden Admin paused or reversed a previous Trump Admin policy that lowered the price of insulin. MORE
Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care
Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE
